Loading clinical trials...

COMPLETEDNA

Dementia Symptom Management at Home Program

A Multisite Cluster RCT of the Dementia Symptom Management at Home Program

NCT03255967•NYU Langone Health

Summary

Alzheimer's Disease and Related Disorders (dementia) poses a significant challenge to our public health. While many persons with dementia are cared for by friends and family in the community with the assistance of home healthcare, most home healthcare clinicians and agencies are ill prepared to care for this population and therefore have difficulty assisting patients and caregivers in maintaining quality of life leading to adverse patient outcomes, increased caregiver stress and burnout, and healthcare utilization. This study will therefore utilize a cluster randomized controlled design at 3 study sites to examine the ability of a multi-component evidence-based practice primary palliative care quality improvement program for home healthcare registered nurses, occupational therapists and physical therapists to improve the quality of life and reduce healthcare utilization for persons with dementia and their informal caregiver.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•PWD over the age of 65
•Admitted to one of the three HHC agencies
•The patient and family caregiver speak English and/or Spanish.
•The informal caregiver is ≥18 years of age and spends at least 8 hours per week with the patient.
•Patients who score ≥6 on the Quick Dementia Rating Scale (at least mild impairment).

Exclusion Criteria

•Patients with a separate Axis 1 diagnosis other than forms of dementia, depression or anxiety.
•PWD residing in assisted living facilities or board and care homes
•PWD solely receiving infusion or home health aide services.

Locations (1)

New York University School of Medicine

New York, New York, United States

Key Dates

Start Date

August 16, 2018

Primary Completion Date

March 31, 2022

Completion Date

May 31, 2022

Last Updated

January 30, 2024

Enrollment

217

ACTUAL participants

Conditions

Dementia

Interventions

DSM-H

BEHAVIORAL

Standard of Care

BEHAVIORAL

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGPHASE3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789

Alzheimer DiseaseDementia+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dementia Symptom Management at Home Program

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Testing the Pain Clinical Practice Guideline

Circadian Rhythm and Other Factors in Memory Clinic Patients

Neurocognitive Assessment Platform 4 Alzheimer